(EMAILWIRE.COM, November 18, 2009 ) Dallas, TX - Cerus Corporation (NASDAQ:CERS) plunged 18.36% to end the day at $2.09 after the company announced that the United States Food And Drug Administration Blood Products Advisory Committee rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential United States Phase III clinical trial of the INTERCEPT Blood System for platelets. The Committee disagreed with the safety margins for the trial proposed by Cerus, and recommended that the trial design include more stringent safety margins for comparing INTERCEPT-treated platelets and conventional platelets.

InterMune, Inc. (NASDAQ:ITMN) decreased 15.76% to close at $11.81 after the company announced that the on going Phase 2b study conducted by Roche of ITMN-191 combined with standard of care PEGASYS and COPEGUS in HCV treatment naive patients has been modified. The Phase 2b study has four dosage cohorts: SOC; 300mg q8h plus SOC; 600mg q12h plus SOC and 900mg q12h plus SOC.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) decreased 9.33% to $11.17 after the company announced that it is offering to sell, to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. BioCryst also intends to grant the underwriters a 30 day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over allotments, if any.

ABOUT http://www.PennyStockPickalert.com

The website alerts investors on Top Stocks that would help investors to generate higher than average returns. These include various types of stocks with huge volume, penny stocks that are moving to the upside quickly, penny stocks with buy signals and companies with news. Our regular Stock pick Alerts helps investors to achieve incredible results in a short amount of time .If you wish to get your company featured on our website then please contact us at info @PennyStockPickReport

Contact Information:
PennyStockPickAlert.com
Robert Wilson
Tel: 214 556 6798
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.